IVD China this week: BSBE, Dirui, Lifotronic and Snibe

Beijing Strong Biotechnologies, Inc. (BSBE) Reports Third-Quarter 2023 Financial Results

On October 25th, Beijing Strong Biotechnologies, Inc. released its third quarter report for 2023, with a revenue of CNY417 million, a year-on-year increase of 1.74%; The net profit attributable to shareholders of the listed company was CNY130 million, a year-on-year increase of 21.90%; The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY130 million, a year-on-year increase of 21.20%.

Dirui Industrial Co., Ltd. Reports Third-Quarter 2023 Financial Results

On October 25th, Dirui Industrial Co., Ltd. released its report for the third quarter of 2023, stating that the company achieved a revenue of CNY1.049 billion, a year-on-year increase of 30.69%; The net profit attributable to shareholders of the listed company was CNY234 million, a year-on-year increase of 20.35%; The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY229 million, a year-on-year increase of 24.14%. 

Shenzhen Lifotronic Technology Co., Ltd. Reports Third-Quarter 2023 Financial Results

On October 25th, Shenzhen Lifotronic Technology Co., Ltd. released its third quarter report for 2023. The company achieved a total operating revenue of CNY809 million, a year-on-year increase of 20.15%, and a net profit attributable to the parent company of CNY205 million, a year-on-year increase of 33.87%.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) Reports Third-Quarter 2023 Financial Results

On October 26th, Shenzhen New Industries Biomedical Engineering Co., Ltd. released its third quarter report for 2023, with a revenue of CNY2.908 billion, a year-on-year increase of 26.62%; The net profit attributable to shareholders of the listed company was CNY1.187 billion, a year-on-year increase of 28.35%; The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY1.102 billion, a year-on-year increase of 29.15%.​